Abstracts tagged "biomarkers and rheumatoid arthritis (RA)"

Abstract Number: 447 • 2013 ACR/ARHP Annual Meeting
High Levels Of Memory B CELLS ARE Associated With Response To A First ANTI-TNF Drug In Patients With Rheumatoid Arthritis
Claire I. Daien^1,2, Sarah Gailhac³, Thibault Mura⁴, Bernard Combe², Michael Hahne¹ and Jacques Morel⁵, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ³Igmm UMR3555, CNRS, Montpellier, France, ⁴CIC, Hopital Gui De Chauliac, Montpellier, France, ⁵Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Tumor necrosis factor (TNF) inhibitors (TNFi) are effective treatments for rheumatoid arthritis (RA). Some reports suggested that TNFi affect B cell homeostasis. We studied…
Abstract Number: 2416 • 2013 ACR/ARHP Annual Meeting
Discovery Of Novel Biomarkers In Rheumatoid Urine : Significance Of Urinary CD14
Yune-Jung Park¹, Hyun-Sook Kim², Seung-Ah Yoo³, Susanna Choi³, Dong-Ho Kim⁴, Chul-Soo Cho⁵ and Wan-Uk Kim⁶, ¹Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University of Korea, Seoul, South Korea, ³Research Institute of Immunobiology, The Catholic University of Korea, Seoul, South Korea, ⁴Research Institute of Immunobiology, Catholic Research Institute of Medical Science, Seoul, Korea., Seoul, South Korea, ⁵Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea, ⁶Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Current serum measures for assessing rheumatoid arthritis (RA) are invasive and are not highly sensitive to changes in disease activity. Thus, there is a…
Abstract Number: 2395 • 2013 ACR/ARHP Annual Meeting
Plasma Short-Talin Is a New Rheumatoid Arthritis Monitoring Biomarker Independent Of The Inflammatory Markers
Kensei Tsuzaka, Masako Takao and Jiro Nishida, Dept of Internal Medicine, Ichikawa General Hospital,TDC, Ichikawa, Chiba, Japan
Methods: ). Sixteen (31.4 %) of these 51 patients were untreated, and 18 patients (35.3%) were treated with biologics DMARD at the time of collecting…
Abstract Number: 2290 • 2013 ACR/ARHP Annual Meeting
Global Metabolite Profiling Of Synovial Fluids From Different Forms Of Inflammatory Arthritis For The Identification Of Putative Biomarker In Rheumatoid Arthritis
Jiwon Hwang¹, Joong Kyong Ahn², Jaejoon Lee¹, Inyoung Kim¹, Seulkee Lee¹, Chan Hong Jeon³, Eun-Mi Koh¹ and Hoon-Suk Cha¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Medicine, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea
Background/Purpose: Metabolomics is the study of unique chemical fingerprints of specific cellular processes. Metabolite profiling is recently applied in identifying biomarkers in medical research including…
Abstract Number: 2289 • 2013 ACR/ARHP Annual Meeting
Correlation Of Anti-Citrullinated Protein and Anti-Carp Antibodies With Disease Duration and Activity In Rheumatoid Arthritis
Michael Mahler¹, Gabriella Lakos¹, Tyler Webb¹, Alvin Yee¹, Leendert A. Trouw² and Pier-Luigi Meroni³, ¹Research, INOVA Diagnostics, San Diego, CA, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Int Medicine, University of Milan, Milano, Italy
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are important serological markers in the diagnosis of rheumatoid arthritis (RA) and are part of the…
Abstract Number: 1737 • 2013 ACR/ARHP Annual Meeting
Association Of HLA-DRB1 Alleles With Clinical Responses To The Anti-Interleukin−17A Monoclonal Antibody Secukinumab In a Cohort Of Patients With Active Rheumatoid Arthritis: An Exploratory Phase 2 Biomarker Study
Gerd Burmester¹, Patrick Durez², Galina Shestakova³, Yue Li⁴, Amanda Wang⁵, Steve Lewitzky⁵, Irina Koroleva⁵, David Lee⁶ and Wolfgang Hueber⁷, ¹Department of Rheumatology & Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ²Université Catholique de Louvain, Brussels, Belgium, ³Kaluga State Pedagogical Tsiolkovsky University, Kaluga, Russia, ⁴IIS, Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharma AG, Cambridge, MA, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Translational Medicine Autoimmunity, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The shared epitope (SE) may play a functional role in RA via Th17/interleukin (IL)-17 polarization (Holoshitz et al. FEBS Lett 2011;585:3619-26). Two phase 2…
Abstract Number: 1393 • 2013 ACR/ARHP Annual Meeting
Survivin But Not Fms-Like Tyrosine Kinase Ligand Is Up-Regulated Before Onset Of Rheumatoid Arthritis
Mikael Brink¹, Maria Bokarewa², Malin Erlandsson³ and Solbritt Rantapää Dahlqvist⁴, ¹Rheumatology, Umeå University, Umea, Sweden, ²Rheumatology and Inflammation Research, Göteborgs University, Göteborg, Sweden, ³Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ⁴Department of Public Health and Clinical Medicine/Rheumatology, Umeå University Hospital, Umeå, Sweden
Background/Purpose: Presence of antibodies against citrullinated peptides (anti-CCP2) and increased levels of cytokines and chemokines precedes the development of rheumatoid arthritis (RA) by several years.…
Abstract Number: 1323 • 2013 ACR/ARHP Annual Meeting
Plasma Leucine-Rich Alpha-2 Glycoprotein Is a Useful Disease Activity Biomarker In Rheumatoid Arthritis
Jung-Soo Song¹, You-Jung Ha², Eun-Jin Kang³, Kwang-Hoon Lee⁴, Sang-Won Lee⁵, Yong-Beom Park⁶, Soo-Kon Lee⁶ and Sang Tae Choi¹, ¹Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ³Rheumatology, Busan Medical Center, Busan, South Korea, ⁴Dongguk University Ilsan Hospital, Goyang, South Korea, ⁵Department of Internal Medicine, Yonsei University College of Medicine, Seoul, NV, South Korea, ⁶Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Leucine-rich a2-glycoprotein (LRG) is a plasma protein which contains leucine-rich repeats (LRRs). Though physiological functions of LRG have not been clarified yet, it has…
Abstract Number: 957 • 2013 ACR/ARHP Annual Meeting
The Role Of S100A4 As a Biological Marker Of Immune Response In Early Rheumatoid Arthritis
Lucie Andrés Cerezo¹, Klára Prajzlerová², Martina Remáková¹, Herman F. Mann³, Michal Tomcík², Karel Pavelka⁴, Jiri Vencovsky² and Ladislav Senolt², ¹Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Institute of Rheumatology, Prague, Czech Republic, ²Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
Background/Purpose: We have previously demonstrated that S100A4 is up-regulated in established rheumatoid arthritis (RA) and that S100A4 regulates apoptosis and synthesis of matrix degrading enzymes…
Abstract Number: 2123 • 2012 ACR/ARHP Annual Meeting
Circulating Mir-223 Is Associated with Disease Activity and May Predict the Response to Therapy in Treatment naïve Patients with Early Rheumatoid Arthritis
Maria Filkova¹, Caroline Ospelt¹, Serena Vettori², Ladislav ŠEnolt³, Herman F. Mann⁴, Beat A. Michel⁵, Jiri Vencovsky⁶, Karel Pavelka³, Renate E. Gay¹, Steffen Gay¹ and Astrid Jüngel², ¹Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Switzerland, Zurich, Switzerland, ²Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ³Institute of Rheumatology, Department of Clinical and Experimental Rheumatology of the 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁶Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Institute of Rheumatology, Prague, Czech Republic
Background/Purpose: Parameters/ predictors of treatment response in patients with early rheumatoid arthritis (ERA) are needed to optimize treatment management based on the expected disease course.…
Abstract Number: 1764 • 2012 ACR/ARHP Annual Meeting
B Cells in Early Rheumatoid Arthritis: ZAP-70 More Than SYK Characterize Seropositive Disease
Anna Laura Fedele, Barbara Tolusso, Elisa Gremese, Silvia Laura Bosello, Angela Carbonella, Silvia Canestri and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: B cells are involved as central players in the pathogenesis of rheumatoid arthritis (RA). Our aim was to define whether a specific B cell…
Abstract Number: 1321 • 2012 ACR/ARHP Annual Meeting
C-Type Lectin Domain Family 4, Member C Gene Expression Level Helps Predict Future Clinical Response to Tabalumab Blockade of B Cell Activating Factor in Rheumatoid Arthritis
Ernst R. Dow¹, Poulabi Banerjee², Michelle A. Penny¹, Eric P. Nantz², Sergey Stepaniants³, Anne Ho³, Wendy J. Komocsar², Pierre-Yves Berclaz² and Robert W. Hoffman¹, ¹Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Indianapolis, IN, ³Covance Genomics Laboratory LLC, Seattle, WA
Background/Purpose: Patients with rheumatoid arthritis (RA) exhibit substantial variability in both the magnitude and duration of their clinical response to treatment. Despite considerable research, no…
Abstract Number: 2664 • 2012 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Tracks Responses in Patients with Rheumatoid Arthritis Treated with Either Adalimumab, Etanercept, and Infliximab
Shintaro Hirata¹, Douglas J. Haney², Guy Cavet², Rebecca Bolce², Wanying Li², Nadine Defranoux², David Chernoff², Kunihiro Yamaoka¹, Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose : Anti-TNF therapy has become a standard therapeutic strategy for treatment of patients with rheumatoid arthritis (RA). A validated multi-biomarker disease activity algorithm (MBDA) blood…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].